Suresh Anaganti

Suresh Anaganti is the CEO of L2P Research Labs since August 2017, specializing in immuno-oncology services, including PDX tumor models and humanized animal models. Previously, Suresh held leadership roles in quality compliance and risk management at Amneal Pharmaceuticals, and served as a research scientist at vivoPharm Pty Ltd. Suresh's academic career includes positions as a research associate at Penn State Health Milton S. Hershey Medical Center, and postdoctoral fellowships at the World Health Organization and the National Cancer Institute, focusing on significant genetic mutations related to cancer. Suresh possesses a PhD in Oncology and Endocrinology from Università degli Studi di Napoli Federico II, a Master's in Biotechnology from Goa University, and a Bachelor's in Chemistry, Dairy Science, and Zoology from Sri Venkateswara University.